JP2023505756A5 - - Google Patents
Info
- Publication number
- JP2023505756A5 JP2023505756A5 JP2022531404A JP2022531404A JP2023505756A5 JP 2023505756 A5 JP2023505756 A5 JP 2023505756A5 JP 2022531404 A JP2022531404 A JP 2022531404A JP 2022531404 A JP2022531404 A JP 2022531404A JP 2023505756 A5 JP2023505756 A5 JP 2023505756A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- polysorbate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940966P | 2019-11-27 | 2019-11-27 | |
| US62/940,966 | 2019-11-27 | ||
| PCT/GB2020/053026 WO2021105694A1 (en) | 2019-11-27 | 2020-11-27 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505756A JP2023505756A (ja) | 2023-02-13 |
| JP2023505756A5 true JP2023505756A5 (enExample) | 2023-12-05 |
Family
ID=73854820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531404A Pending JP2023505756A (ja) | 2019-11-27 | 2020-11-27 | ＥｐｈＡ２に特異的な二環式ペプチドリガンドおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230025916A1 (enExample) |
| EP (1) | EP4065085A1 (enExample) |
| JP (1) | JP2023505756A (enExample) |
| KR (1) | KR20220131898A (enExample) |
| CN (1) | CN114760988A (enExample) |
| AU (1) | AU2020392890B2 (enExample) |
| CA (1) | CA3158741A1 (enExample) |
| IL (1) | IL293200A (enExample) |
| MX (1) | MX2022006001A (enExample) |
| WO (1) | WO2021105694A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| CA3095582A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| EP4165414A1 (en) * | 2020-06-12 | 2023-04-19 | BicycleTX Limited | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| EP4382130A4 (en) * | 2021-08-17 | 2025-12-24 | Tianjin Conjustar Biologics Co Ltd | Conjugated polypeptide-drug with a novel structure and its application |
| EP4719480A1 (en) * | 2023-06-01 | 2026-04-08 | BicycleTx Limited | Bicyclic peptide ligands specific for epha2 and uses thereof |
| WO2024248860A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for epha2 and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
-
2020
- 2020-11-27 CN CN202080082789.3A patent/CN114760988A/zh active Pending
- 2020-11-27 US US17/779,226 patent/US20230025916A1/en not_active Abandoned
- 2020-11-27 EP EP20825161.1A patent/EP4065085A1/en active Pending
- 2020-11-27 CA CA3158741A patent/CA3158741A1/en active Pending
- 2020-11-27 AU AU2020392890A patent/AU2020392890B2/en active Active
- 2020-11-27 KR KR1020227021780A patent/KR20220131898A/ko active Pending
- 2020-11-27 WO PCT/GB2020/053026 patent/WO2021105694A1/en not_active Ceased
- 2020-11-27 MX MX2022006001A patent/MX2022006001A/es unknown
- 2020-11-27 JP JP2022531404A patent/JP2023505756A/ja active Pending
- 2020-11-27 IL IL293200A patent/IL293200A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526451A5 (enExample) | ||
| JP2024543505A5 (enExample) | ||
| US11866500B2 (en) | Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers | |
| Vail et al. | Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies | |
| Ye et al. | Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review | |
| CN104955452B (zh) | 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途 | |
| JP2022527334A5 (enExample) | ||
| JP2005506294A (ja) | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 | |
| JP2023102786A5 (enExample) | ||
| KR20100017752A (ko) | 빈플루닌 및 트라스투주맙을 포함하는 암 치료 병용요법 | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| Arai et al. | Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1 | |
| KR101978108B1 (ko) | 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제 | |
| JP2024519449A5 (enExample) | ||
| JP2023548303A5 (enExample) | ||
| Huang et al. | Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| Inohara et al. | Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study | |
| WO2024255214A1 (zh) | 2,3,-环鸟苷酸-核苷酸钠在制备抗肿瘤药物中的用途 | |
| WO2024120461A1 (zh) | Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用 | |
| Xue et al. | Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer: A case report | |
| Kudo | Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? | |
| CN1383382A (zh) | 甲氧基吗啉代阿霉素在治疗肝肿瘤方面的应用 | |
| Liu et al. | Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 |